Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

NCT05326425 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Jin Hyoung Kang